HK1026637A1 - Compositions for administering taxanes orally to human patients and their use - Google Patents

Compositions for administering taxanes orally to human patients and their use

Info

Publication number
HK1026637A1
HK1026637A1 HK00105943A HK00105943A HK1026637A1 HK 1026637 A1 HK1026637 A1 HK 1026637A1 HK 00105943 A HK00105943 A HK 00105943A HK 00105943 A HK00105943 A HK 00105943A HK 1026637 A1 HK1026637 A1 HK 1026637A1
Authority
HK
Hong Kong
Prior art keywords
compositions
human patients
administering taxanes
taxanes orally
orally
Prior art date
Application number
HK00105943A
Other languages
English (en)
Inventor
Samuel Broder
Kenneth L Duchin
Sami Selim
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Publication of HK1026637A1 publication Critical patent/HK1026637A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK00105943A 1997-05-27 2000-09-20 Compositions for administering taxanes orally to human patients and their use HK1026637A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86351397A 1997-05-27 1997-05-27
PCT/US1998/007776 WO1998053811A1 (en) 1997-05-27 1998-04-22 Method and compositions for administering taxanes orally to human patients

Publications (1)

Publication Number Publication Date
HK1026637A1 true HK1026637A1 (en) 2000-12-22

Family

ID=25341241

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00105943A HK1026637A1 (en) 1997-05-27 2000-09-20 Compositions for administering taxanes orally to human patients and their use

Country Status (23)

Country Link
EP (1) EP0994706B1 (pt)
JP (1) JP2002500667A (pt)
KR (1) KR100615783B1 (pt)
CN (2) CN1261275A (pt)
AR (1) AR012731A1 (pt)
AT (1) ATE308365T1 (pt)
AU (1) AU7130098A (pt)
BR (1) BR9809694A (pt)
CA (1) CA2290446C (pt)
CZ (1) CZ9904244A3 (pt)
DE (1) DE69832173T2 (pt)
DK (1) DK0994706T3 (pt)
ES (1) ES2247690T3 (pt)
HK (1) HK1026637A1 (pt)
HU (1) HUP0003546A3 (pt)
IL (2) IL132992A0 (pt)
NO (1) NO995812L (pt)
PL (1) PL337064A1 (pt)
RU (1) RU2205005C2 (pt)
SK (1) SK157599A3 (pt)
UA (1) UA74767C2 (pt)
WO (1) WO1998053811A1 (pt)
ZA (1) ZA984268B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
AU3574097A (en) * 1997-06-20 1999-01-04 Baker Norton Pharmaceuticals, Inc. Soluble prodrugs of paclitaxel
GB9718903D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
EP1749540B1 (en) 1999-05-17 2010-10-13 Cancer Research Ventures Limited Compositions for improving bioavailability of orally administered drugs
HUP0203303A3 (en) * 1999-10-27 2005-01-28 Baker Norton Pharma Compositions for administering taxanes orally to human patients
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
EP1365759A2 (en) * 2001-01-18 2003-12-03 PHARMACIA & UPJOHN COMPANY Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1623706A3 (en) * 2001-02-28 2006-02-22 Bristol-Myers Squibb Company Metronomic dosing of taxanes for inhibiting tumor growth
UY27185A1 (es) * 2001-02-28 2002-09-30 Bristol Myers Squibb Co Dosificación metronómica de taxanos
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ596868A (en) * 2009-06-02 2014-04-30 Nikan Pharmaceuticals Llc Antagonism of human formyl peptide receptor for treatment of disease
EP4059497A1 (en) * 2021-03-17 2022-09-21 Dompé farmaceutici S.p.a. C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP4308114A1 (en) * 2021-03-17 2024-01-24 Dompe' Farmaceutici SpA C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411947A (en) * 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
CZ283038B6 (cs) * 1991-01-11 1997-12-17 Laboratoires Glaxo Sa Akridinové deriváty, způsob výroby a farmaceutické prostředky s jejich obsahem
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
ES2126919T3 (es) * 1994-07-26 1999-04-01 Indena Spa Taxanos semisinteticos con actividad antitumoral.
TW354293B (en) * 1995-06-06 1999-03-11 Bristol Myers Squibb Co Prodrugs of paclitaxel derivatives
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2221444A1 (en) * 1996-01-31 1997-08-07 Steven B. Hansel A method of making pharmaceutically active taxanes orally bioavailable
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU756752B2 (en) * 1998-04-01 2003-01-23 Skyepharma Canada Inc. Anticancer compositions

Also Published As

Publication number Publication date
CN1550231A (zh) 2004-12-01
KR100615783B1 (ko) 2006-08-25
NO995812D0 (no) 1999-11-26
IL132992A (en) 2006-08-20
WO1998053811A1 (en) 1998-12-03
ATE308365T1 (de) 2005-11-15
RU2205005C2 (ru) 2003-05-27
ES2247690T3 (es) 2006-03-01
BR9809694A (pt) 2000-10-03
DE69832173T2 (de) 2006-08-03
ZA984268B (en) 1999-06-23
UA74767C2 (en) 2006-02-15
EP0994706A4 (en) 2001-05-16
CZ9904244A3 (cs) 2001-10-17
JP2002500667A (ja) 2002-01-08
IL132992A0 (en) 2001-03-19
EP0994706A1 (en) 2000-04-26
AR012731A1 (es) 2000-11-08
KR20010013025A (ko) 2001-02-26
PL337064A1 (en) 2000-07-31
HUP0003546A3 (en) 2002-12-28
AU7130098A (en) 1998-12-30
CA2290446C (en) 2008-01-29
NO995812L (no) 2000-01-25
HUP0003546A2 (hu) 2002-11-28
SK157599A3 (en) 2002-10-08
EP0994706B1 (en) 2005-11-02
CA2290446A1 (en) 1998-12-03
DK0994706T3 (da) 2006-03-06
CN1261275A (zh) 2000-07-26
DE69832173D1 (de) 2005-12-08

Similar Documents

Publication Publication Date Title
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
HUP0103357A3 (en) Halichondrin analogs and methods of their use and preparation
IL114586A (en) Droloxifene for use in the treatment of cardiovascular diseases and pharmaceutical compositions comprising same
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR USE THEREOF
HU9901570D0 (en) Use of nanodispersions in pharmaceutical compositions
HUP0300836A3 (en) Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
HUP0101293A3 (en) Aspb28-human insulin comprising pharmaceutical composition administered by inhalation and their use
IL130784A0 (en) Use of an anti-cd40l compound in the manufacture of a medicament for treating a patient with immune complex disease and pharmaceutical compositions containing the same
IL127943A (en) Pharmaceutical and cosmetic compositions for the treatment of skin disorders
EP1129217A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES
HUP0003133A2 (en) Ace-inhibitor nitric salts and use of them for producing pharmaceutical compositions
HK1026637A1 (en) Compositions for administering taxanes orally to human patients and their use
HUP0004096A3 (en) Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
AU9018898A (en) Phosphazole-containing nucleoside analogs, related compounds, pharmaceutical compositions thereof, and their use in in vitro medicinal treatments
HUP0202862A3 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
IL149360A0 (en) Method and compositions for administering taxanes orally to human patients
EP1181022A4 (en) MEDICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
HUP9904027A3 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0001526A3 (en) Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
HUP0003244A3 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
AU5587800A (en) S-(+)-desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
AU2742395A (en) Therapeutic or dietetic composition in the form of medicinal gel for the administration to pets

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090422